Phase 3 randomised-withdrawal trial in adults with endogenous hypercortisolism: among 62 responders randomised, more patients with hypertension lost control on placebo than on continued relacorilant (difference 34%; OR 0.17). Acne and bursitis occurred only with relacorilant.
RCTn = 62
Pivonello et al. Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study